Boehringer Ingelheim (BI) has gained another approval for its pulmonary fibrosis drug Ofev from the FDA, for targeting a wider spectrum of patients with interstitial lung disease (ILD). The FDA has approved Ofev for treating chronic fibrosing ILDs with a progressive phenotype, and Boehringer’s drug is the first to be registered in the US for
NICE published a final recommendation for AbbVie and Boehringer Ingelheim’s Risankizumab today, completing fast-track process that sees the psoriasis treatment gain market access in record time. The drug is one of the first treatments to go through NICE’s fast-track appraisal system, which accelerates the review process, whilst also cutting the standard 90-day implementation period down
Boehringer Ingelheim announces the FDA has granted Fast Track designation to nintedanib for the treatment of systemic sclerosis with associated interstitial lung disease (SSc-ILD). The FDA’s Fast Track designation enables development of new therapies that treat serious conditions and fulfil an unmet medical need in an effort to get treatments to those in need sooner.
Boehringer Ingelheim has recently won its first biosimilar approval in Europe with authorisation of Cyltezo for a variety of chronic inflammatory conditions, which includes rheumatoid arthritis, psoriatic arthritis, Crohn’s disease and ulcerative colitis. Cyltezo is a biosimilar of AbbVie’s Humira, an anti-TNF monoclonal antibody that pulls in annual sales of approximately $15 billion across its
Cost regulators have approved the routine use of Boehringer Ingelheim’s Ofev as a treatment for some patients with lung-scarring disease, idiopathic pulmonary fibrosis, on the NHS in England and Wales.
Nineteen new therapies, which include an antidote to the blood thinner Pradaxa, a treatment for the rare blood cancer multiple myeloma, and a new drug for Parkinson’s disease. Have taken a leap closer to being granted entry to the EU market. The European Medicines Agency’s Committee for Medicinal Products for Human Use has endorsed approval
The Scottish Medicines Consortium (SMC) have issued final advice recommending the approval of Boehringer Ingelheim’s Trajenta with insulin to treat adults with type 2 diabetes to improve glycaemic control. The recommendation follows a Health Technology Appraisal accepting Trajenta (linagliptin) for treatment in combination with insulin with or without metformin, when insulin alone, with diet and
Boehringer Ingelheim and Eli Lilly Diabetes Alliance have announced that regulators for the National Health Service in England have deemed their drug, Jardiance (empagliflozin), as value for money. The drug has been recommended by the National Institute for Health and Care Excellence (NICE) for treating some patients with type II diabetes. The endorsement is a
Boehringher Ingelheim announced yesterday that the European Commission has granted marketing authorisation for their Vargatef (nintedanib). Vargatef is a triple angiokinase inhibitor for the treatment of lung cancer patients. The drug has been approved when used in combination with docetaxel for adult patients with locally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC)
England and Wales’ cost regulator, NICE, have released draft regulatory guidance recommending the expanded use of Boehringer Ingelheim’s clot buster drug Pradaxa on the National Health Service (NHS). The National Institute for Health and Care Excellence (NICE) has endorsed the drug to treat and prevent recurrent and potentially fatal blood clots in the legs and
